HSPA9 and cancer: Disrupting the interaction between GRP75 and p53 by the potent anti-cancer drug, MKT-077 [52] or GRP75 binding peptide activates endogenous p53, thus preventing cell growth of osteosarcoma and breast carcinoma cells [49].